How Much Is a Microdose of Tirzepatide: The Reported Range, and Why It Has No Clinical Definition

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Compliance note

This page provides numeric context for a patient-reported practice. It is not a prescribing recommendation. Microdose tirzepatide is not an FDA-recognized regimen. No phase 2 or phase 3 trial has tested sub-therapeutic tirzepatide doses for weight or metabolic outcomes. Discuss any dose change with your prescriber before making it.

Key Takeaways

• Patient-reported tirzepatide microdoses fall in the 0.5 to 2.5 mg per week range, with 1.0 mg as the most commonly reported starting point
• The FDA-approved starting dose of 2.5 mg weekly is itself a non-therapeutic titration step; it is intended for 4 weeks before increasing to 5 mg
• "Microdose" is a patient-coined term with no clinical or regulatory definition; clinical bodies do not endorse a specific sub-2.5 mg range
• Below 0.5 mg weekly, dose accuracy with insulin syringes becomes a serious technical concern, particularly at high compounded concentrations
• The dose-response relationship below 2.5 mg has not been characterized in clinical trials

Direct answer

A "microdose" of tirzepatide is most commonly 1.0 mg per week in patient-community usage, with the broader microdose range spanning 0.5 to 2.5 mg per week. The FDA-approved starting dose is 2.5 mg per week. Doses below 2.5 mg are outside FDA-labeled use and have not been studied in registration trials. The term has no clinical body's definition behind it; it is a community label applied to sub-FDA-starting doses. This page describes the numeric landscape of what users report. It is not a prescribing recommendation.

Table of contents

1. The FDA-approved tirzepatide dose ladder
2. Where microdoses sit relative to the dose ladder
3. The 1.0 mg starting microdose pattern
4. Why 2.5 mg itself is not therapeutic
5. The dose accuracy floor at very small volumes
6. What we know and don't know about the dose-response curve
7. How dose corresponds to volume at common concentrations
8. The cross-drug comparison: tirzepatide vs semaglutide microdose
9. The maintenance step-down case
10. The contrary view: is there a meaningful threshold below standard dose
11. FAQ
12. Sources

The FDA-approved tirzepatide dose ladder

The FDA-approved titration schedule for both Mounjaro and Zepbound:

Weeks	Dose	Status
1 to 4	2.5 mg weekly	Starting / titration; non-therapeutic
5 to 8	5 mg weekly	First therapeutic dose
9 to 12	7.5 mg weekly	Intermediate dose
13 to 16	10 mg weekly	Maintenance option
17 to 20	12.5 mg weekly	Maintenance option
21+	15 mg weekly	Maximum / maintenance

The label is clear that 2.5 mg is a titration step intended for the first 4 weeks of treatment. It is not a maintenance dose. Patients who stay at 2.5 mg long-term are doing so off-label even though the dose itself is in the FDA-labeled range.

Where microdoses sit relative to the dose ladder

Patient-reported microdoses sit below the FDA titration ladder entirely:

Dose	Status	Source of guidance
15 mg weekly	FDA maximum maintenance	SURMOUNT-1 protocol
10 mg weekly	FDA maintenance option	SURMOUNT-1 protocol
5 mg weekly	First therapeutic dose	FDA label
2.5 mg weekly	FDA starting / titration only	FDA label
2.0 mg weekly	Microdose (upper)	Patient communities
1.25 mg weekly	Microdose (half-starting)	Patient communities
1.0 mg weekly	Microdose (common entry)	Patient communities
0.5 mg weekly	Microdose (low)	Patient communities
Below 0.5 mg	Sub-microdose	Patient communities

Every entry above 2.5 mg is FDA-approved at a specific titration step. Every entry below 2.5 mg is outside FDA-labeled use and exists in patient practice without clinical trial validation.

The 1.0 mg starting microdose pattern

The most commonly described entry point in patient communities is 1.0 mg weekly. The reasons users describe choosing this number:

• It is 40 percent of the FDA starting dose, a round and easy-to-remember fraction
• At 5 mg/mL compounded concentration, 1.0 mg is 0.20 mL or 20 units on an insulin syringe, which is well within accurate measurement range
• It is roughly half of the upper microdose range, leaving room to titrate up or down
• It is the most-recommended number in microdose-focused subreddits, which creates self-reinforcing community consensus

None of these are clinical justifications. They are practical and social reasons for a community standard.

Why 2.5 mg itself is not therapeutic

An underappreciated point in the microdose conversation: the FDA-approved 2.5 mg starting dose is not intended to produce weight loss. It is a titration step to acclimate the patient to GI effects before reaching the first therapeutic dose at 5 mg. The pivotal SURMOUNT trials evaluated outcomes at 5 mg, 10 mg, and 15 mg, not at 2.5 mg.

This matters because it changes the framing of microdose discussion. If 2.5 mg itself was not expected to produce meaningful weight loss in trial design, then doses below 2.5 mg are even further from validated therapeutic activity. Patient reports of weight loss at 1.0 mg microdose, if real, are happening at a dose that is one-fifth of the lowest dose the manufacturer tested for outcomes.

The dose accuracy floor at very small volumes

Below 0.5 mg weekly, the dose accuracy problem becomes significant. At a 10 mg/mL compounded concentration, 0.5 mg is 0.05 mL or 5 units. At 0.25 mg, it is 0.025 mL or 2.5 units, which cannot be measured precisely on a standard 1-unit-graduated insulin syringe.

The practical accuracy floor for patient-administered insulin-syringe draws is approximately 0.025 mL or 2.5 units. Below this, the dose error margin exceeds 50 percent. This is a mechanical reason patient practice rarely goes below 0.5 mg weekly. It is not a clinical guideline; it is a measurement constraint.

What we know and don't know about the dose-response curve

What is known: SURMOUNT-1 showed approximately dose-proportional weight loss across 5 mg, 10 mg, and 15 mg weekly tirzepatide, with mean weight loss of 16%, 21.4%, and 22.5% respectively at 72 weeks. The curve flattens at higher doses, which is consistent with receptor saturation.

What is not known: the shape of the curve below 5 mg. Three possibilities:

• Linear extrapolation: 2.5 mg produces ~10%, 1.25 mg produces ~5%, 0.5 mg produces ~2%. This is the most optimistic reading.
• Threshold effect: below some receptor occupancy threshold, weight loss drops to near zero. Microdoses would produce minimal effect.
• Non-monotonic: sub-therapeutic doses might produce paradoxical or non-linear effects through differential receptor activity.

None of these have been tested. The honest answer is that we don't know what 1.0 mg weekly tirzepatide does on average for weight outcomes.

How dose corresponds to volume at common concentrations

For patients who want to understand the math without using it as a how-to:

Concentration	1.0 mg volume	Insulin syringe units
5 mg/mL	0.20 mL	20 units
10 mg/mL	0.10 mL	10 units
20 mg/mL	0.05 mL	5 units
40 mg/mL	0.025 mL	2.5 units

Lower concentrations produce larger and more accurately measurable volumes. This is one reason 5 mg/mL is the most commonly described compounding concentration for microdose users.

The cross-drug comparison: tirzepatide vs semaglutide microdose

A 1.0 mg microdose of tirzepatide is not the same as a 1.0 mg dose of semaglutide. The two drugs have different mg-scale potencies and different receptor profiles. A 1.0 mg dose of semaglutide is in the FDA-approved Ozempic maintenance range. A 1.0 mg dose of tirzepatide is in the patient-defined microdose range.

This is sometimes a source of confusion in cross-platform patient discussion. "I am on 1 mg" means different things depending on the drug. When evaluating any microdose reference, the drug name matters as much as the number.

The maintenance step-down case

For a patient who reached their goal weight on standard-dose tirzepatide and is stepping down, microdose ranges have a different clinical context than they do for initiation. SURMOUNT-4 demonstrated that continued exposure preserves maintenance, although the trial used full doses. A step-down to 1.0 to 2.0 mg for maintenance is sometimes used in clinical practice, with the same caveat that it is off-label.

The patient who is asking "how much is a microdose" because they are stepping down has a different evidence base than the patient asking because they are starting. The conversation with the prescriber should reflect that difference.

The contrary view: is there a meaningful threshold below standard dose

One reasonable counter to the "no evidence" framing: drug receptor pharmacology generally produces graded effects, not all-or-nothing thresholds. If 2.5 mg produces measurable receptor occupancy (which it does, based on pharmacokinetic data), then 1.0 mg produces approximately 40 percent of that occupancy, which is non-zero. Whether 40 percent receptor occupancy produces clinically meaningful weight or metabolic effects is the empirical question that has not been answered.

The counter to the counter: clinical relevance is not just receptor occupancy. Many drugs have therapeutic thresholds where activity is real but clinically insufficient. GLP-1 receptor activation needs to be sustained at adequate levels to produce sustained appetite reduction and gastric delay. Whether sub-therapeutic doses cross that threshold consistently is unknown.

The honest position: receptor pharmacology suggests some pharmacological activity at microdose levels. Clinical activity at meaningful magnitudes is unmeasured.

FAQ

How much is a microdose of tirzepatide? Patient-reported range is 0.5 to 2.5 mg weekly, with 1.0 mg as the most commonly described starting point.

Is 1 mg a tirzepatide microdose? Yes, by patient-community definition. 1 mg is 40 percent of the FDA starting dose.

Is 2 mg a microdose? By patient-community definition, yes. 2 mg is 80 percent of FDA starting.

What is the lowest patient-reported dose? Reports go as low as 0.25 to 0.5 mg weekly. At these levels, measurement accuracy becomes a real concern.

Why is 2.5 mg the FDA starting dose if it is non-therapeutic? It is a titration step to manage GI side effects before reaching 5 mg, the first therapeutic dose.

How does dose scale with effect at low doses? Unknown. The curve has been measured at 5/10/15 mg, not below.

What volume is 1 mg? 0.20 mL at 5 mg/mL, 0.10 mL at 10 mg/mL, 0.05 mL at 20 mg/mL.

What is the equivalent semaglutide dose? No direct mg-to-mg conversion. Different drugs, different receptors, different potencies.

Do clinical bodies define a microdose range? No. Microdose is a patient-coined term with no clinical or regulatory definition.

Is there a meaningful threshold below standard dose? Mechanistically plausible. Clinically unmeasured.

What is the most common microdose? 1.0 mg weekly in patient-community usage.

Does microdose maintenance differ from initiation? Yes. SURMOUNT-4 supports maintenance with continued exposure. Initiation at microdose has no trial evidence base.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
3. Wadden TA et al. Tirzepatide After Intensive Lifestyle Intervention (SURMOUNT-3). Nature Medicine. 2023.
4. FDA Prescribing Information. Mounjaro (tirzepatide). Eli Lilly. Revised 2024.
5. FDA Prescribing Information. Zepbound (tirzepatide). Eli Lilly. Revised 2024.
6. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. FDA Guidance on Compounding Under Section 503A. 2023.
8. Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2023.
9. American Association of Clinical Endocrinologists. Obesity Algorithm. 2024.
10. FDA Adverse Event Reporting System (FAERS). Public Dashboard. Accessed 2026.
11. USP General Chapter on Injectable Drug Products. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with licensed providers and U.S.-based pharmacies. This article provides numeric context for a patient-reported practice. It is not a prescribing recommendation.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions and is not interchangeable with brand-name Mounjaro or Zepbound.

Results Disclaimer. Tirzepatide microdosing is not an FDA-recognized regimen. The numeric ranges described reflect patient-community usage, not clinical guidance. No clinical trial has tested sub-therapeutic tirzepatide doses for weight or metabolic outcomes. Discuss any dose modification with your prescriber.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.